All IndicationsOncology
🎗️
Cutaneous T Cell Lymphoma
1
Companies
1
Drug Programs
0
Phase 3
0
Upcoming PDUFAs
Competitors
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| GALDY Galderma Group AG/ADR | CD11301 0.03% | Phase 2 | — | — | — |
Development Stage Distribution
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.
